Biotechnology company MabCure Inc has generated a panel of 10 novel monoclonal antibodies (MAbs) against prostate cancer. These MAbs were selected from more than 30,000 MAbs produced by MabCure’s proprietary technology.
The 10 selected MAbs were shown to be all highly specific to prostate cancer cells without any cross reaction with other cancers or with healthy human serum tested. MabCure intends to screen these MAbs in clinical studies in order to select the few that provide the highest specificity and sensitivity in diagnosing prostate cancer in the blood and urine of patients.
“Our goal is to develop a highly reliable yet simple blood or urine test that will allow physicians to diagnose prostate cancer in its early stages, when the disease is largely curable,” said MabCure CEO, Dr. Amnon Gonenne. “Our newly generated panel of anti-prostate cancer MAbs has demonstrated the desired diagnostic properties in preclinical studies, which now gives us the opportunity to evaluate their individual performance in a clinical setting and bring us closer to our goal.”
MabCure’s antibodies are directed against tumor specific antigens that are, based on early evidence, unique to prostate cancer and could lead to a specific and accurate blood or urine test for the detection of prostate cancer.
According to Dr. Gonenne, plans for a clinical study to select the best performing MAbs are underway.
Source: MabCure Inc
